Login to Your Account

Clinic Roundup

Monday, April 8, 2013
• Emergent BioSolutions Inc., of Rockville, Md., expanded the protocol for its ongoing Phase Ib, single-arm, open-label study (Protocol 16009) that is evaluating the safety and efficacy of TRU-016 in combination with rituximab in previously untreated patients with chronic lymphocytic leukemia (CLL).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription